Gilead Sciences, Inc. $GILD Shares Acquired by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 322.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,000 shares of the biopharmaceutical company’s stock after purchasing an additional 29,000 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Gilead Sciences were worth $4,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $27,000. Putney Financial Group LLC raised its holdings in Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares during the period. Finally, Howard Hughes Medical Institute purchased a new position in Gilead Sciences during the second quarter worth approximately $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $122.60 on Tuesday. The company has a market cap of $152.11 billion, a P/E ratio of 19.01, a P/E/G ratio of 0.64 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $89.02 and a twelve month high of $128.70. The company’s 50-day moving average price is $123.28 and its 200-day moving average price is $117.77. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the firm earned $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total transaction of $625,400.00. Following the transaction, the director owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $124.83, for a total value of $1,248,300.00. Following the sale, the chief executive officer directly owned 566,698 shares of the company’s stock, valued at approximately $70,740,911.34. This trade represents a 1.73% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 136,257 shares of company stock worth $16,855,192. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on GILD shares. Wolfe Research reaffirmed an “outperform” rating and set a $150.00 target price on shares of Gilead Sciences in a research note on Monday, December 15th. Daiwa Capital Markets lifted their target price on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Sanford C. Bernstein set a $135.00 target price on shares of Gilead Sciences and gave the stock an “outperform” rating in a research note on Monday, December 29th. Mizuho raised their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.20.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.